Safety and immunogenicity of commercial Hepatitis B vaccines. |
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension |
rTMS-stroke-phase I |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
Retrospective observational study of the administration of Jusvinza, for the management of COVID-19 at the Hospital “Dr. Luis Diaz Soto”. |
Results of an antimicrobial stewardship program |
Rectal ozone therapy in high-risk symptomatic SARS-CoV-2 positive patients |
Rectal Ozone in the COVID-19 treatment |
Recombinant interferon alpha-2b in paranoid schizophrenia. |
Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis. |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks. |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months. |
Randomized double blind controlled, phase I clinical trial, to assess safety, reactogenicity and immunogenicity of the 638 vaccine candidate, in healthy female and male children and adolescents aged from 5 to 17 years old from Cienfuegos Province, Cuba. |
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer |
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. |
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory |
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series |